Strategic Data Partnerships Character Bio's integrated genetic and longitudinal ophthalmology data from 150+ clinics creates a unique asset for biomarker discovery and trial design. Propose enterprise data licensing or joint development collaborations with pharma/biotech partners to improve patient stratification and trial enrichment, emphasizing privacy and AI-driven insights.

Trial Enablement With lead programs CTX114 and CTX203 advancing toward clinical trials, there is an opportunity to offer trial design support, site selection optimization, and real-time patient matching using the AI platform to accelerate enrollment and ensure relevant endpoints.

Pharma Validation Sanofi Ventures participation signals pharma validation, opening opportunities for co-development, licensing, or strategic partnerships around AMD precision therapies to leverage Character Bio's platform for faster drug candidates.

Platform Licensing The AI-powered platform combining genomics, multi-modal data, and machine learning can be offered as a data analytics and decision-support service to biotech sponsors, CROs, and academic groups seeking faster target discovery and patient stratification in ocular diseases.

Ophthalmology Partnerships Historically collaborating with Bausch + Lomb demonstrates ability to engage ophthalmology leaders; pursue expansions with device makers, clinics, and payers to co-develop solutions, expand data sources, and validate real-world utility.